News & Events

Recent Press Releases

GeneCentric Therapeutics to Present First Data on Cancer Subtyping Platform for Bladder Cancer, Potential for Use as Drug Response Biomarker

GeneCentric Therapeutics announced today that it will present the first data on the application of its proprietary Cancer Subtyping Platform (CSP®) to bladder cancer and its potential utility to provide drug response biomarkers for the disease. The gene expression subtyping data will be presented in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL on June 2, 2018.

GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cancer

DURHAM, N.C., January 3, 2018 — GeneCentric Therapeutics, Inc. today announced a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP®) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC).  As part of the research collaboration, GeneCentric will apply its lung cancer subtyping profilers (LSP™) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes.

GeneCentric Therapeutics CEO and Founder Dr. Myla-Lai Goldman to be featured on ”Radio In Vivo: Your Link to the Triangle Science Community!” November 1, 2017

Durham, NC, November 1 , 2017 – GeneCentric Therapeutics Founder and CEO, Dr. Myla-Lai Goldman, will be featured today on the radio show ”Radio In Vivo: Your Link to the Triangle Science Community!”, from 11:00am-12:00pm, ET, on WCOM – FM103.5, based in Carrboro, NC.

Recent News

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

GeneCentric to Present at the Personalized Medicine World Conference

On January 26, 2016 at 2:00 pm, GeneCentric’s Hawazin Faruki will speak at the Personalized Medicine World Conference (PMWC) 2016 Silicon Valley on “Genomic Tumor Profiling – Advancing Beyond Gene Mutations.” PMWC 2016 SV, co-hosted with Stanford Health Care and UCSF on January 24-27, will gather 1200 multidisciplinary attendees and key stakeholders from the business, […]

GeneCentric Selected to Participate in the Southeast Venture Philanthropy Summit

On May 5, 2015, GeneCentric will present at the Southeast Investor & Venture Philanthropy Oncology Summit 2015. The Summit features more than 30 of the Southeast’s top private oncology companies. Attendees come from small and large oncology-focused companies, venture philanthropies and investment groups.